ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI was downgraded by equities research analysts at Oppenheimer from an "outperform" rating to a "market perform" rating in a research report issued to clients and investors on Monday, Briefing.com reports.
Separately, Piper Sandler cut ESSA Pharma from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $15.00 to $2.00 in a research note on Monday.
Read Our Latest Stock Report on EPIX
NASDAQ EPIX opened at $1.40 on Monday. The company has a 50-day moving average price of $5.88 and a two-hundred day moving average price of $5.68. ESSA Pharma has a 52 week low of $1.40 and a 52 week high of $11.67. The stock has a market cap of $62.12 million, a price-to-earnings ratio of -2.26 and a beta of 1.84.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.10. As a group, equities research analysts expect that ESSA Pharma will post -0.71 earnings per share for the current fiscal year.
A hedge fund recently raised its stake in ESSA Pharma stock. Janus Henderson Group PLC raised its position in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI by 7.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,175,242 shares of the company's stock after purchasing an additional 85,760 shares during the quarter. Janus Henderson Group PLC owned about 2.66% of ESSA Pharma worth $9,978,000 as of its most recent SEC filing. Institutional investors and hedge funds own 75.12% of the company's stock.
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.